济川药业：公司主动撤回此前递交的依坦进口生物制品上市申请

Core Viewpoint - Jichuan Pharmaceutical (600566) has decided to fully implement the localization strategy for the recombinant human growth hormone injection, Yitan, in response to the development trends of the Chinese growth hormone market and the national new drug localization policy [1] Group 1: Strategic Decisions - The company has completed the technology transfer and process optimization for Yitan growth hormone α, with localization production capacity fully ready [1] - The clinical trial for the bioequivalence of imported and localized products has been approved by the National Medical Products Administration (NMPA) and has been initiated [1] Group 2: Market Focus - The company has proactively withdrawn its previous application for the import of the Yitan biological product to focus on the rapid submission of the localization application [1]